Stock Track | Travere Therapeutics Plunges 8% After Pricing $125 Million Public Offering

Stock Track

Nov 08, 2024

Shares of Travere Therapeutics, Inc. (TVTX) plummeted nearly 8% on Thursday, November 8th, after the biopharmaceutical company announced the pricing of a public offering of common stock that could dilute existing shareholders.

On Wednesday evening, November 7th, Travere Therapeutics revealed that it had priced an underwritten public offering of approximately 7.81 million shares of its common stock at $16 per share. The offering is expected to raise gross proceeds of $125 million for the company.

The news of the share issuance was met with a significant sell-off, as investors anticipated a dilutive impact on the company's outstanding shares. Travere Therapeutics' stock opened at $17.25 on November 8th but quickly shed nearly 8% of its value, closing the trading session at $15.88.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1130637698"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1130637698\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1130637698?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-08 17:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1130637698","market":"us","top_or_hot":-1,"title":"Stock Track | Travere Therapeutics Plunges 8% After Pricing $125 Million Public Offering","media":"Stock Track","content":"<p>Shares of Travere Therapeutics, Inc. (TVTX) plummeted nearly 8% on Thursday, November 8th, after the biopharmaceutical company announced the pricing of a public offering of common stock that could dilute existing shareholders.</p>\n\n<p>On Wednesday evening, November 7th, Travere Therapeutics revealed that it had priced an underwritten public offering of approximately 7.81 million shares of its common stock at $16 per share. The offering is expected to raise gross proceeds of $125 million for the company.</p>\n\n<p>The news of the share issuance was met with a significant sell-off, as investors anticipated a dilutive impact on the company's outstanding shares. Travere Therapeutics' stock opened at $17.25 on November 8th but quickly shed nearly 8% of its value, closing the trading session at $15.88.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Travere Therapeutics Plunges 8% After Pricing $125 Million Public Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Travere Therapeutics Plunges 8% After Pricing $125 Million Public Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-11-08 17:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Travere Therapeutics, Inc. (TVTX) plummeted nearly 8% on Thursday, November 8th, after the biopharmaceutical company announced the pricing of a public offering of common stock that could dilute existing shareholders.</p>\n\n<p>On Wednesday evening, November 7th, Travere Therapeutics revealed that it had priced an underwritten public offering of approximately 7.81 million shares of its common stock at $16 per share. The offering is expected to raise gross proceeds of $125 million for the company.</p>\n\n<p>The news of the share issuance was met with a significant sell-off, as investors anticipated a dilutive impact on the company's outstanding shares. Travere Therapeutics' stock opened at $17.25 on November 8th but quickly shed nearly 8% of its value, closing the trading session at $15.88.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TVTX","symbol_name":"Travere Therapeutics, Inc.","start_time":0,"source_url":"","article_id":"1130637698","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1130637698","pubTimestamp":1731059537,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Travere Therapeutics, Inc.  plummeted nearly 8% on Thursday, November 8th, after the biopharmaceutical company announced the pricing of a public offering of common stock that could dilute existing shareholders.On Wednesday evening, November 7th, Travere Therapeutics revealed that it had priced an underwritten public offering of approximately 7.81 million shares of its common stock at $16 per share. The offering is expected to raise gross proceeds of $125 million for the company.The new","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TVTX":"Travere Therapeutics, Inc."},"translate_title":"Travere Therapeutics公开发行1.25亿美元后股价暴跌8%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TVTX":1},"content_text":"Shares of Travere Therapeutics, Inc. (TVTX) plummeted nearly 8% on Thursday, November 8th, after the biopharmaceutical company announced the pricing of a public offering of common stock that could dilute existing shareholders.\nOn Wednesday evening, November 7th, Travere Therapeutics revealed that it had priced an underwritten public offering of approximately 7.81 million shares of its common stock at $16 per share. The offering is expected to raise gross proceeds of $125 million for the company.\nThe news of the share issuance was met with a significant sell-off, as investors anticipated a dilutive impact on the company's outstanding shares. Travere Therapeutics' stock opened at $17.25 on November 8th but quickly shed nearly 8% of its value, closing the trading session at $15.88.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}